Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$13.23 USD

13.23
8,144,660

-0.45 (-3.29%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $13.24 +0.01 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for June 10th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Dentsply (XRAY) Up 22.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

New Strong Sell Stocks for June 5th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.

Zacks Equity Research

Dentsply International (XRAY) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 4.88% and -0.29%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.

Zacks Equity Research

Earnings Preview: Dentsply International (XRAY) Q1 Earnings Expected to Decline

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanghamitra Saha headshot

First US Payroll Crash Since 2010: What's Hot, What's Not

by Sanghamitra Saha

U.S. payroll numbers in March were lackluster. We have highlighted a few industries that survived the coronavirus threat in March and also the ones that succumbed.

Zacks Equity Research

Dentsply (XRAY) Down 17.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Align Technology to Acquire exocad in Digital Dentistry Space

by Zacks Equity Research

This acquisition is expected to boost Align Technology's (ALGN) portfolio of Invisalign and iTero digital solutions.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q4 Earnings Lag Estimates, Sales Rise

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) gains from the Technologies & Equipment arm in Q4.

Zacks Equity Research

Dentsply International (XRAY) Q4 Earnings Lag Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of -1.35% and 2.11%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

STERIS' (STE) Growth Picture Impressive Amid Rising Costs

by Zacks Equity Research

STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.

Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Zacks Equity Research

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

Zacks Equity Research

Dentsply International (XRAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Abbott's Alliance With Insulet to Fortify Diabetic Care Unit

by Zacks Equity Research

Both Abbott (ABT) and Insulet will use a pay-as-you-go model to enhance customer acceptance.

Zacks Equity Research

Integra LifeSciences Grows Organically Amid Supply Issues

by Zacks Equity Research

Integra LifeSciences' (IART) Codman Specialty Surgical segment registers impressive organic growth in Q4.

Zacks Equity Research

Integer Holdings Acquires Inomec, Extends Global Foothold

by Zacks Equity Research

Integer Holdings' (ITGR) Inomec buyout is likely to boost R&D pipeline and also strengthen and expand global foothold.

Zacks Equity Research

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

Zacks Equity Research

Here's Why You Should Invest in Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

Sreyoshi Mukherjee headshot

Bleak Outlook for Medical Dental Supplies Industry

by Sreyoshi Mukherjee

Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.

Zacks Equity Research

XRAY or CNMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

by Zacks Equity Research

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

Zacks Equity Research

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

by Zacks Equity Research

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.